Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 2 , Pages 99-107, February 2009

Pharmacotherapy of Pediatric Insomnia

  • Christopher J. Kratochvil, M.D. (Assistant Editor)
    • ,
  • Judith A. Owens, M.D., M.P.H.

      Affiliations

    • Corresponding Author InformationCorrespondence to Judith Owens, M.D., M.P.H., Division of Pediatric Ambulatory Medicine, Rhode Island Hospital, 593 Eddy Street, Potter Bldg., Suite 200, Providence, RI 02903

Dr. Owens is with the Division of Pediatric Ambulatory Medicine, Rhode Island Hospital

Accepted 6 October 2008.

Disclosure: Dr. Owens has received grants from Sepracor, Eli Lilly, Cephalon, Johnson & Johnson, Boehringer-Ingleheim, and Shire. She has served as a consultant for Cephalon, Shire, Johnson & Johnson, Sanofi-Aventis, McNeil, Boehringer-Ingleheim, and Takeda. She has served on the speakers' bureaus of Johnson & Johnson, Eli Lilly, and Sanofi-Aventis. She has served on the advisory boards of Select Comfort, Eli Lilly, Cephalon, Pfizer, and Respironics.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines but rather examples of the thought process that may go into pharmacotherapy decision making.

PII: S0890-8567(09)60003-4

doi:10.1097/CHI.0b013e3181930639

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 2 , Pages 99-107, February 2009

Article Tools